Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mark Houston, Mimi Guarneri & Joel Kahn. (2015) The appropriate clinical use of niacin in the treatment of dyslipidemia. Clinical Lipidology 10:1, pages 17-22.
Read now
Read now
Articles from other publishers (18)
O. A. Gromova & I. Yu. Torshin. (2023) Systematic analysis of the experimental and clinical pharmacology of nicotinamide and prospects for the treatment of atherosclerosis. Experimental and Clinical Gastroenterology:10, pages 111-125.
Crossref
Crossref
Michele Scognamiglio, Dario Costa, Antonio Sorriento & Claudio Napoli. (2019) Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Current Pharmaceutical Design 25:1, pages 85-95.
Crossref
Crossref
Nicholas J. Woudberg, Sarah Pedretti, Sandrine Lecour, Rainer Schulz, Nicolas Vuilleumier, Richard W. James & Miguel A. Frias. (2018) Pharmacological Intervention to Modulate HDL: What Do We Target?. Frontiers in Pharmacology 8.
Crossref
Crossref
Margery A. Connelly, Irina Shalaurova & James D. Otvos. (2016) High-density lipoprotein and inflammation in cardiovascular disease. Translational Research 173, pages 7-18.
Crossref
Crossref
Gabriele Cioni, Lucia Mannini, Alessandrello Agatina Liotta, Giovanna D’Alessandri, Cinzia Fatini, Brunella Bandinelli, Maria Costanzo, Rosanna Abbate & Rossella Marcucci. (2015) Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels. Journal of Thrombosis and Thrombolysis 41:3, pages 433-435.
Crossref
Crossref
Sebnem Garip, Sevgi Haman Bayari, Mete Severcan, Sherif Abbas, Igor K. Lednev & Feride Severcan. (2016) Structural effects of simvastatin on rat liver tissue: Fourier transform infrared and Raman microspectroscopic studies. Journal of Biomedical Optics 21:2, pages 025008.
Crossref
Crossref
Ulrich Julius. (2015) Niacin as antidyslipidemic drug. Canadian Journal of Physiology and Pharmacology 93:12, pages 1043-1054.
Crossref
Crossref
Preethi Mani & Anand Rohatgi. (2015) Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. Current Atherosclerosis Reports 17:8.
Crossref
Crossref
F. Alexandre, V.H.S. Zago, N.B. Panzoldo, E.S. Parra, D.Z. Scherrer, F. Vendrame, V.S. Nunes, E.I.L. Gomes, P.D. Marcato, E.R. Nakandakare, E.C.R. Quintão & E.C. de Faria. (2015) Reference values for high-density lipoprotein particle size and volume by dynamic light scattering in a Brazilian population sample and their relationships with metabolic parameters. Clinica Chimica Acta 442, pages 63-72.
Crossref
Crossref
Pingping Zhang, Yantong Sun, Guobing Shi, Yin Sui, Qiuying Li, Yunbiao Tang & Jingkai Gu. (2015) Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers. International Journal of Analytical Chemistry 2015, pages 1-9.
Crossref
Crossref
Rui-Xia Xu, Yuan-Lin Guo, Xiao-Lin Li, Sha Li & Jian-Jun Li. (2014) Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clinical and Experimental Pharmacology and Physiology 41:7, pages 475-481.
Crossref
Crossref
Wakana Ohashi & Yuichi Hattori. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
807
819
.
Henry A. Tran, Arthur Z. Schwartzbard & James A. Underberg. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
399
413
.
Eliot A. Brinton. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
373
398
.
Ngoc‐Anh Le, Ran Jin, Joanne E. Tomassini, Andrew M. Tershakovec, David R. Neff & Peter W.F. Wilson. (2013) Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients. Journal of the American Heart Association 2:4.
Crossref
Crossref
Dragana Nikolic, Niki Katsiki, Giuseppe Montalto, Esma Isenovic, Dimitri Mikhailidis & Manfredi Rizzo. (2013) Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. Nutrients 5:3, pages 928-948.
Crossref
Crossref
Juliana Sih, Shyam S. Bansal, Stefano Filipini, Silvia Ferrati, Kunal Raghuwansi, Erika Zabre, Eugenia Nicolov, Daniel Fine, Mauro Ferrari, Ganesh Palapattu & Alessandro Grattoni. (2012) Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: new perspectives on promoting heart health. Analytical and Bioanalytical Chemistry 405:5, pages 1547-1557.
Crossref
Crossref
U. Julius & S. Fischer. (2013) Nicotinic acid as a lipid-modifying drug – A review. Atherosclerosis Supplements 14:1, pages 7-13.
Crossref
Crossref